ProCE Banner Activity

How I Choose Newer Agents for Patients With Advanced Renal Cell Carcinoma

Clinical Thought
With the plethora of new drugs, combination regimens, and approaches for RCC, selecting the right agent can be challenging for clinicians.

Released: February 27, 2017

Expiration: February 26, 2018

No longer available for credit.

Share

Faculty

Robert Motzer

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Exelixis

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Motzer, MD, has disclosed that he has received consulting fees from Eisai, Exelixis, Novartis, and Pfizer.